ライフサイエンスコーパス: plasmapheresis

1 ia purpura, and recovered after therapy with plasmapheresis.

2 ectomy plus eculizumab (n=5), in addition to plasmapheresis.

3 aving metalloprotease by plasma infusion and plasmapheresis.

4 may respond to intravenous immunoglobulin or plasmapheresis.

5 espite treatment with fresh-frozen plasma or plasmapheresis.

6 no deaths among the 13 patients who received plasmapheresis.

7 ofile of IVIg would appear to be superior to plasmapheresis.

8 lication of HIV infection and may respond to plasmapheresis.

9 sed (one of five), and one of five underwent plasmapheresis.

10 phosphamide, intravenous immunoglobulins, or plasmapheresis.

11 bserved after rituximab; no patient required plasmapheresis.

12 ith similar death-censored graft survival to plasmapheresis.

13 d retinopathy improved in all patients after plasmapheresis.

14 inal vein by laser Doppler, before and after plasmapheresis.

15 imab dose and 4 bortezomib doses preceded by plasmapheresis.

16 requiring thymoglobulin, IVIg, rituximab, or plasmapheresis.

17 s, 3 deceased), 21 of whom had pretransplant plasmapheresis.

18 Systemic therapies included plasmapheresis (18), chemotherapy (30), blood transfusio

19 ravenous immune globulin, 3 of 4 treated and plasmapheresis, 3 of 4 treated).

20 lasmapheresis than among those who underwent plasmapheresis (50% compared with 24%; P < 0.05).

21 Ten patients received plasmapheresis, 6 eculizumab, and 7 a combination of bot

22 llowed by a 2-week cycle on days 1-4-8-11 of plasmapheresis and 1.3 mg/m(2) bortezomib; then 0.5 mg/k

23 eracute rejection protocol applied including plasmapheresis and antithymocyte globulin treatment as w

24 essfully reversed with the implementation of plasmapheresis and cessation of clopidogrel and cyclospo

25 nimally beneficial, but after treatment with plasmapheresis and corticosteroids, she was still asympt

26 Past protocols to desensitize patients using plasmapheresis and cyclophosphamide have not been broadl

27 We conclude that plasmapheresis and heme-albumin are of benefit in EPP co

28 ful treatment of the patient with additional plasmapheresis and heme-albumin with improvement of hepa

29 Treatment with plasmapheresis and high-dose corticosteroids may be effe

30 ted a patient with EPP who was improved with plasmapheresis and i.v. heme-albumin before OLT.

31 techniques such as intravenous immunoglobin, plasmapheresis and immuno-adsorption.

32 Other options include plasmapheresis and intravenous immunoglobulin (IVIg), co

33 Perioperative treatment with plasmapheresis and intravenous immunoglobulin (IVIG), co

34 Both plasmapheresis and intravenous immunoglobulin may be emp

35 gated whether cyclophosphamide combined with plasmapheresis and intravenous immunoglobulins is an opt

36 significantly higher PRA, and received more plasmapheresis and IVIG at the time of transplant.

37 -blood compatible columns, double-filtration plasmapheresis and lipoprotein (a)-apheresis.

38 Plasmapheresis and low-dose CMV-Ig combined with traditi

39 During this time, experience with both plasmapheresis and renal replacement therapy has become

40 Days 2-4: daily plasmapheresis and replacement of the shed plasma with 6

41 f bortezomib (1.3 mg/m(2)) over 2 weeks with plasmapheresis and rituximab.

42 cluded in a protocol involving pretransplant plasmapheresis and splenectomy at the time of transplant

43 Plasmapheresis and tacrolimus-mycophenolate mofetil resc

44 Plasmapheresis and the addition of cyclophosphamide led

45 The patient responded dramatically to plasmapheresis and the addition of high-dose corticoster

46 We used a protocol that included plasmapheresis and the administration of low-dose intrav

47 l antibodies and complement were depleted by plasmapheresis and the use of Gal alpha1-3Gal column ads

48 ter pretransplant conditioning regimen using plasmapheresis and/or intravenous immunoglobulin therapy

49 atients, for whom treatment with thymectomy, plasmapheresis, and conventional immunotherapeutic agent

50 levels and included thymoglobulin induction, plasmapheresis, and intravenous immunoglobulin in the hi

51 Immunomodulatory agents, such as steroids, plasmapheresis, and intravenous immunoglobulin, seem to

52 ol involved pretransplant immunosuppression, plasmapheresis, and low-dose intravenous immunoglobulin+

53 avenous heparin, intravenous gamma globulin, plasmapheresis, and/or antiproliferative agents.

54 Rapid diagnosis and treatment that includes plasmapheresis are critical for improved survival.

55 n we describe our center's experience with a plasmapheresis-based desensitization protocol for highly

56 des further evidence of the high efficacy of plasmapheresis-based desensitization protocols.

57 antigen antibodies (DSA) can be overcome by plasmapheresis-based strategies with some success in ren

58 In three patients who received plasmapheresis before bortezomib, plasmapheresis failed

59 ch case, the recipient had been treated with plasmapheresis before transplantation because of a posit

60 lowing two kinds of protein depletion: batch plasmapheresis (BP; n = 5) and thoracic duct drainage (T

61 Although plasmapheresis caused a similar reduction in alloreactiv

62 in 8 patients and were unchanged in 1 after plasmapheresis, chemotherapy, or both.

63 us renal replacement therapy, in addition to plasmapheresis, corticosteroids, cyclophosphamide, and r

64 Treatment for HR included plasmapheresis, cyclophosphamide, and rituximab.

65 as higher in several other groups, including plasmapheresis donors (34.0%), intravenous drug users (8

66 However, continuous plasmapheresis dramatically increased the tumor-to-backg

67 All patients received plasmapheresis every other day with intravenous immune g

68 o received plasmapheresis before bortezomib, plasmapheresis failed to reduce DSA.

69 esensitization, after desensitization (using plasmapheresis followed by 100 mg/kg intravenous immunog

70 ts treated with alternate-day, single-volume plasmapheresis followed by low-dose cytomegalovirus (CMV

71 to October of 1998, five patients underwent plasmapheresis for PNF after other causes of immediate a

72 ee patients were treated with eculizumab and plasmapheresis for recurrent aHUS after kidney transplan

73 versity Medical Center for consideration for plasmapheresis for the presumed essential type III cryog

74 rolimus was discontinued, and treatment with plasmapheresis, fresh frozen plasma, steroids, and OKT3

75 All recipients who underwent plasmapheresis had restoration of liver function.

76 ntravenous immunoglobulin is increasing, but plasmapheresis has not been shown to be of benefit.

77 Intravenous heme and plasmapheresis have been proposed but not previously rep

78 ng steroids, intravenous immunoglobulin, and plasmapheresis have shown limited efficacy in IgM monocl

79 In spite of steroid treatment and plasmapheresis, his clinical status deteriorated rapidly

80 He was managed initially with plasmapheresis, hypertransfusion, and infusions of i.v.

81 ys after transplantation, which responded to plasmapheresis, i.v.IG, and rituximab.

82 efractory to aggressive treatment, including plasmapheresis, immunosuppression with prednisolone, and

83 ne to two cycles (1.3 mg/m(2) x 4 doses) and plasmapheresis in 2008 to remove HLA antibodies posttran

84 n 3, OKT3 for concurrent rejection in 3, and plasmapheresis in 5 patients.

85 ulinemia treated successfully with long-term plasmapheresis in conjunction with thalidomide and dexam

86 The role of plasmapheresis in liver failure and hepatic coma remains

87 This report reviews the use of plasmapheresis in primary hepatic allograft nonfunction

88 s of action, the efficacy, and the safety of plasmapheresis in rheumatic diseases demonstrates that t

89 After plasmapheresis in six patients with recurrences, the per

90 anisms that explain the efficacy of repeated plasmapheresis in this setting are suggested.

91 either intravenous immunoglobulin (IVIg) or plasmapheresis, in conjunction with cyclophosphamide.

92 e 3 hemolytic uremic syndrome, not requiring plasmapheresis, in two patients (6%).

93 mplement has been treated by combinations of plasmapheresis, intravenous gamma-globulin and monoclona

94 mpatible recipients, and was reversible with plasmapheresis, intravenous immunoglobulin, and increasi

95 nti-human leukocyte antigen antibodies using plasmapheresis, intravenous immunoglobulin, and rituxima

96 All had received previous treatment with plasmapheresis, intravenous immunoglobulin, and rituxima

97 , and prednisone combined with pretransplant plasmapheresis, intravenous immunoglobulin, and splenect

98 ts treated with more than four pretransplant plasmapheresis/intravenous immunoglobulin (PP/IVIg) had

99 The immunosuppressive protocol consisted of plasmapheresis/intravenous immunoglobulin infusion befor

100 fter kidney transplantation by rituximab and plasmapheresis is ambiguous.

101 Plasmapheresis is effective in reversing HVS-related ret

102 Plasmapheresis is known to reduce serum viscosity (SV) a

103 ole of corticosteroids, immune globulin, and plasmapheresis is uncertain.

104 Combinations that include plasmapheresis, IVIG, cyclophosphamide, and rituximab ha

105 , addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4).

106 ine A, mycophenolate mofetil, gammaglobulin, plasmapheresis, LJP 394, flaxseed oil, bindarit, anti-CD

107 Patients' plasmapheresis material was tested for the presence of a

108 Although plasmapheresis may ameliorate acute allograft disease, s

109 The long-term use of plasmapheresis may be a well-tolerated treatment option

110 Plasmapheresis may have a more consistent response rate

111 It has been suggested that plasmapheresis may improve coagulopathy and prevent blee

112 ents treated with eculizumab (n = 11) and/or plasmapheresis (n = 13) during the acute phase of HUS ha

113 venous immunoglobulins (n = 71/74; 96%), and plasmapheresis (n = 17/74; 23%).

114 ytotoxic (CDC) crossmatch (XM) pretransplant plasmapheresis, nine had positive flow cytometric (FC) X

115 o halt the progression of CAPS, but repeated plasmapheresis not only halted the condition, but it led

116 this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal he

117 s/arm; range, 5-23), of which, four examined plasmapheresis (one suggested benefit) and one for immun

118 We did not rely on plasmapheresis or anti-A titer determinations.

119 teinuria that may remit after treatment with plasmapheresis or immunoadsorption.

120 C4d deposition was not treated with plasmapheresis or intravenous immunoglobulin and was not

121 Eighteen patients (78%) were treated with plasmapheresis or low-dose IVIg+rituximab; 11 (49%) with

122 medications as needed, and consideration of plasmapheresis or use of immunoadsorption column in seve

123 lowering serum suPAR concentrations through plasmapheresis, or by interfering with the suPAR-beta(3)

124 Plasmapheresis, or TPE, removes monoclonal antibodies, i

125 She responded to repeated plasmapheresis over 3 years.

126 in total plasma protein concentration after plasmapheresis (p < .05).

127 apy was administered per package insert with plasmapheresis performed immediately before each bortezo

128 t regimens commonly include a combination of plasmapheresis (PL) and intravenous immunoglobulin (IVIG

129 The comparative efficacy of plasmapheresis (PLEX) vs immunoglobulin as maintenance t

130 Plasmapheresis (PP) and intravenous immunoglobulin (IVIg

131 t survival of patients with AHR treated with plasmapheresis (PP) and intravenous immunoglobulin (IVIG

132 This patient received one plasmapheresis (PP) and intravenous immunoglobulin (IVIg

133 Plasmapheresis (PP) has been shown to remove HLA- specif

134 Plasmapheresis (PP) has been used in the treatment of va

135 Predicting recurrence and response to plasmapheresis (PP) or other interventions remains probl

136 97+/-3% vs. 76+/-20%, P=NS) and after 3 IVIg/plasmapheresis (PP) treatments but lower among responder

137 nts with anti-A1 titers > or = 1:8 underwent plasmapheresis (PP).

138 been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous imm

139 ansplant using an intravenous immunoglobulin/plasmapheresis preconditioning regimen with interleukin-

140 body-mediated rejection and graft loss using plasmapheresis preconditioning, low-dose intravenous imm

141 Apart from drastic measures such as extended plasmapheresis, pretargeting selectivity was neither sen

142 DSAs were removed with plasmapheresis pretransplant, and patients did not routi

143 These patients underwent two to five plasmapheresis procedures during which one plasma volume

144 Plasmapheresis provides an effective treatment option fo

145 antibody and a more intensive posttransplant plasmapheresis regiment aimed at maintaining low levels

146 All patients treated with bortezomib/plasmapheresis resulted in a primary DSA reduction of mo

147 Plasmapheresis resulted in significant reductions in ser

148 Treatment interventions included plasmapheresis, resulting in functional improvement: the

149 ata indicate that proteasome inhibitors plus plasmapheresis results in prolonged reduction of HLA ant

150 erapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, c

151 A median (interquartile range) of 15 (10-23) plasmapheresis sessions was administered; 13 of the subj

152 Plasmapheresis should be considered for symptomatic hype

153 Repeated plasmapheresis should be considered in the most refracto

154 Plasmapheresis should be used for patients with symptoma

155 cannot give a simple answer to the question: plasmapheresis-take it or leave it?

156 , intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomide, cyclophosphamide, hemoperfu

157 her among patients who were not treated with plasmapheresis than among those who underwent plasmapher

158 Pretransplant the patients received plasmapheresis three times weekly for a planned maximum

159 It is postulated that perhaps plasmapheresis, through removal of cytokines or other me

160 Patients were treated with plasmapheresis, thymoglobulin/OKT3, and corticosteroids.

161 the failure of corticosteroid, rituximab and plasmapheresis to attenuate the rate of decline in allog

162 bbit (r) ATG can be used in combination with plasmapheresis to effectively treat antibody-mediated re

163 recipient cross-match were desensitized with plasmapheresis to permit live donor (LD) transplantation

164 Attempts to deal with this problem have used plasmapheresis to remove antibodies or high-dose pooled

165 ma IgM levels were measured before and after plasmapheresis treatment.

166 bulin cross-match-negative after one to five plasmapheresis treatments and underwent LD transplantati

167 a pretransplant conditioning regimen of four plasmapheresis treatments followed by intravenous immuno

168 An initial short course of 5 plasmapheresis treatments improved the patient's cutaneo

169 y-four patients had a median of 2 additional plasmapheresis treatments to reach the preoperative targ

170 nts with non-antigen-specific IA, additional plasmapheresis treatments were necessary for recipient d

171 x treatments with antigen-specific IA and 12 plasmapheresis treatments, one patient with a starting i

172 us immunoglobulin therapy, a 3-day course of plasmapheresis was administered.

173 Moreover, plasmapheresis was associated with an unacceptably high

174 Once plasmapheresis was initiated, she required no further tr

175 versible hemolytic uremic syndrome requiring plasmapheresis was observed in one patient with NHL duri

176 Plasmapheresis was performed for severe cases (n = 10).

177 Plasmapheresis was planned for up to 3 months after LDLT

178 persistence of the woman's ulcers, intensive plasmapheresis was resumed and continued 3 to 4 times pe

179 Rejections requiring plasmapheresis were found only among patients with T-pos

180 he fifth postoperative day and completion of plasmapheresis when a repeated retrospective cross-match

181 eaths occurring in patients not treated with plasmapheresis, whereas there were no deaths among the 1

182 esistant to steroids, cyclophos-phamide, and plasmapheresis who responded to the addition of anti-CD2

183 ntinuation of FK506, anticoagulation, and/or plasmapheresis with fresh-frozen plasma exchange, resolv

184 ipients continued to receive every other day plasmapheresis with intravenous immune globulin for the

185 of a desensitization protocol also involving plasmapheresis) with specimens obtained in 91 patients w

186 He was treated with steroids and plasmapheresis, with mild improvement in vision.

187 the offending antibody may be possible with plasmapheresis, without the expectation for significant